Brainstorm Cell Therapeutics | BCLI - Selling And Administration Expenses


Brainstorm Cell Therapeutics reported $1.78M in Selling and Administration Expenses for its fiscal quarter ending in March of 2025.





Selling And Administration Expenses Change Date
Alterity Therapeutics Limited AUD 2.29M 649.1K Jun/2023
Biogen USD 545.2M 38.6M Sep/2025
Brainstorm Cell Therapeutics USD 1.78M 319K Mar/2025
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.33M 50K Sep/2025
CSL USD 1.23B 498M Dec/2025
Cytokinetics USD 91.72M 67.02M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Grifols EUR 333.1M 157M Sep/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Mesoblast USD 28.54M 9.69M Dec/2025